当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Hari Krishna Shriwas1*, Surafel Shibiru2 , Abel Debebe2
Hypertrophic Lichen Planus (HLP) is a subacute or chronic variant of lichen planus (LP) of unknown etiology. It is an inflammatory disorder in which T‑lymphocytes attack the basal epidermis, producing characteristic clinical and histological lesions. It occurs in middle age, and women are commonly affected than men. It is characterized by epidermal hyperplasia in response to persistent itch and gets intense by stress. Squamous cell carcinoma, keratoacanthomas developing on the HLP of lower limbs have been reported. Most recent conventional treatment of the HLP and LP disorders consists the use of topical and systemic corticosteroid, psoralen and ultraviolet A therapy, immunosuppressant, systemic retinoid, cyclosporine, and acitretin. All these drugs are proved to reduce the symptoms temporarily. In Ayurveda, this condition may be considered under Charma Kushtha, a type of Kshudra Kushtha (minor skin diseases), due to the similarity in signs and symptoms with HLP. Charma Kushtha is dominant of Vata Dosha and Kapha Dosha. In this condition, the skin over the patch becomes thick like the skin of an elephant (lichenification).